loading
Schlusskurs vom Vortag:
$1.40
Offen:
$1.41
24-Stunden-Volumen:
166.63K
Relative Volume:
0.47
Marktkapitalisierung:
$91.70M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.04M
KGV:
-0.8343
EPS:
-1.69
Netto-Cashflow:
$-27.38M
1W Leistung:
-6.00%
1M Leistung:
-6.00%
6M Leistung:
-25.40%
1J Leistung:
+2.92%
1-Tages-Spanne:
Value
$1.30
$1.42
1-Wochen-Bereich:
Value
$1.30
$1.52
52-Wochen-Spanne:
Value
$1.08
$3.79

Regulus Therapeutics Inc Stock (RGLS) Company Profile

Name
Firmenname
Regulus Therapeutics Inc
Name
Telefon
858-202-6300
Name
Adresse
4224 CAMPUS POINT COURT, SAN DIEGO, CA
Name
Mitarbeiter
32
Name
Twitter
@regulusrx
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
RGLS's Discussions on Twitter

Vergleichen Sie RGLS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
RGLS 1.42 91.70M 0 -30.04M -27.38M -1.69
VRTX 449.99 115.43B 10.63B -479.80M -1.35B 13.33
REGN 747.38 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 591.88 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.13 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 107.68 24.89B 3.30B -501.07M 1.03B 11.54

Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-08-02 Eingeleitet Oppenheimer Outperform
2024-03-18 Eingeleitet Leerink Partners Outperform
2018-03-28 Eingeleitet B. Riley FBR, Inc. Neutral
2018-01-05 Eingeleitet Leerink Partners Outperform
2017-06-13 Bestätigt Chardan Capital Markets Buy
2017-03-06 Bestätigt Wedbush Outperform
2017-01-30 Herabstufung Needham Buy → Hold
2017-01-30 Herabstufung Wells Fargo Outperform → Market Perform
2016-12-07 Bestätigt Chardan Capital Markets Buy
2016-11-02 Bestätigt Needham Buy
2016-07-25 Bestätigt Chardan Capital Markets Buy
2016-06-28 Bestätigt Chardan Capital Markets Buy
2016-06-28 Bestätigt FBR Capital Outperform
2016-06-28 Bestätigt Needham Buy
2016-06-07 Bestätigt Chardan Capital Markets Buy
2016-04-13 Eingeleitet Chardan Capital Markets Buy
2015-12-04 Eingeleitet Wells Fargo Outperform
2015-06-09 Eingeleitet Guggenheim Buy
2015-04-21 Fortgesetzt FBR Capital Outperform
2014-11-24 Eingeleitet Deutsche Bank Buy
2014-08-07 Bestätigt FBR Capital Outperform
2013-08-14 Bestätigt Needham Buy
Alle ansehen

Regulus Therapeutics Inc Aktie (RGLS) Neueste Nachrichten

pulisher
Nov 16, 2024

Annovis Bio (NYSE:ANVS) versus Regulus Therapeutics (NASDAQ:RGLS) Head-To-Head Contrast - Defense World

Nov 16, 2024
pulisher
Nov 15, 2024

Biotechnology Value Fund L.P. Increases Stake in Regulus Therape - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

What is HC Wainwright’s Estimate for RGLS FY2024 Earnings? - Defense World

Nov 15, 2024
pulisher
Nov 14, 2024

FY2024 Earnings Forecast for RGLS Issued By HC Wainwright - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Creative Planning Makes New Investment in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World

Nov 14, 2024
pulisher
Nov 11, 2024

Regulus Therapeutics (NASDAQ:RGLS) Receives Buy Rating from HC Wainwright - MarketBeat

Nov 11, 2024
pulisher
Nov 07, 2024

Regulus: Q3 Earnings Snapshot - San Francisco Chronicle

Nov 07, 2024
pulisher
Nov 07, 2024

Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates - PR Newswire

Nov 07, 2024
pulisher
Nov 06, 2024

Regulus Therapeutics (RGLS) Stock Price, News & Analysis - MarketBeat

Nov 06, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in Regulus Therapeuti - GuruFocus.com

Nov 05, 2024
pulisher
Oct 30, 2024

HC Wainwright Reiterates Buy Rating for Regulus Therapeutics (NASDAQ:RGLS) - MarketBeat

Oct 30, 2024
pulisher
Oct 29, 2024

Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average PT from Analysts - MarketBeat

Oct 29, 2024
pulisher
Oct 24, 2024

Regulus Therapeutics secures exclusive license for kidney disease treatment - Investing.com India

Oct 24, 2024
pulisher
Oct 24, 2024

Regulus Therapeutics secures exclusive license for kidney disease treatment By Investing.com - Investing.com South Africa

Oct 24, 2024
pulisher
Oct 24, 2024

Regulus Therapeutics Inc. Enters into Patent & Technology License Agreement with the Board of Regents of the University of Texas System - Marketscreener.com

Oct 24, 2024
pulisher
Oct 19, 2024

Financial Survey: Regulus Therapeutics (NASDAQ:RGLS) & Ironwood Pharmaceuticals (NASDAQ:IRWD) - Defense World

Oct 19, 2024
pulisher
Oct 13, 2024

Renaissance Technologies LLC Has $211,000 Position in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World

Oct 13, 2024
pulisher
Oct 08, 2024

HC Wainwright Reaffirms "Buy" Rating for Regulus Therapeutics (NASDAQ:RGLS) - MarketBeat

Oct 08, 2024
pulisher
Oct 08, 2024

RGLSRegulus Therapeutics Inc. Latest Stock News & Market Updates - StockTitan

Oct 08, 2024
pulisher
Oct 08, 2024

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) - PR Newswire

Oct 08, 2024
pulisher
Oct 04, 2024

Analysts Set Regulus Therapeutics Inc. (NASDAQ:RGLS) PT at $10.80 - MarketBeat

Oct 04, 2024
pulisher
Oct 03, 2024

Company’s Banking Stock: Dissecting a -7.22% Quarterly Revenue Decline Amid Growth - The InvestChronicle

Oct 03, 2024
pulisher
Oct 03, 2024

Regulus Therapeutics Inc [RGLS] stock for 7,280 USD was acquired by Collier Kathryn J - Knox Daily

Oct 03, 2024
pulisher
Sep 28, 2024

Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Sold by CVI Holdings LLC - MarketBeat

Sep 28, 2024
pulisher
Sep 28, 2024

Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth - Simply Wall St

Sep 28, 2024
pulisher
Sep 24, 2024

ProMIS Neurosciences (NASDAQ:PMN) versus Regulus Therapeutics (NASDAQ:RGLS) Critical Contrast - Defense World

Sep 24, 2024
pulisher
Sep 23, 2024

Investing in Regulus Therapeutics Inc (RGLS) Is Getting More Attractive - Knox Daily

Sep 23, 2024
pulisher
Sep 23, 2024

Victory Capital Management Inc. Has $645,000 Position in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World

Sep 23, 2024
pulisher
Sep 19, 2024

Regulus Therapeutics (NASDAQ:RGLS) Stock Rating Upgraded by StockNews.com - Defense World

Sep 19, 2024
pulisher
Sep 17, 2024

Regulus Therapeutics (NASDAQ:RGLS) Upgraded to "Sell" by StockNews.com - MarketBeat

Sep 17, 2024
pulisher
Sep 11, 2024

Oppenheimer’s latest rating for RGLS stock - Knox Daily

Sep 11, 2024
pulisher
Sep 09, 2024

RGLS stock rated an Outperform by Oppenheimer - Knox Daily

Sep 09, 2024
pulisher
Sep 09, 2024

Gaining Ground: Regulus Therapeutics Inc (RGLS) Closes Lower at 1.46, Down -6.41 - The Dwinnex

Sep 09, 2024
pulisher
Sep 09, 2024

Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Sep 09, 2024
pulisher
Sep 06, 2024

Regulus Therapeutics (NASDAQ:RGLS) Raised to Sell at StockNews.com - MarketBeat

Sep 06, 2024
pulisher
Sep 05, 2024

Regulus Therapeutics Inc [RGLS] Director makes an insider purchase of 4,000 shares worth 7280.0. - Knox Daily

Sep 05, 2024
pulisher
Sep 02, 2024

Regulus Therapeutics Inc (RGLS) rating initates by Oppenheimer - Knox Daily

Sep 02, 2024
pulisher
Sep 02, 2024

How does Regulus Therapeutics Inc (RGLS) change from a tortoise to a hare? - SETE News

Sep 02, 2024
pulisher
Sep 02, 2024

Regulus Therapeutics Inc (RGLS) stock analysis: A comprehensive overview - US Post News

Sep 02, 2024
pulisher
Aug 28, 2024

Regulus Therapeutics Inc (RGLS)’s stock chart: A technical perspective - US Post News

Aug 28, 2024
pulisher
Aug 28, 2024

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences - StockTitan

Aug 28, 2024
pulisher
Aug 27, 2024

The Attractiveness of Investing In Regulus Therapeutics Inc (RGLS) is Growing - Knox Daily

Aug 27, 2024
pulisher
Aug 21, 2024

Market Recap: Regulus Therapeutics Inc (RGLS)’s Positive Momentum, Closing at 1.59 - The Dwinnex

Aug 21, 2024
pulisher
Aug 21, 2024

A Guide To The Risks Of Investing In Regulus Therapeutics Inc (RGLS) - Knox Daily

Aug 21, 2024
pulisher
Aug 20, 2024

Vanguard Group Inc. Has $2.13 Million Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) - MarketBeat

Aug 20, 2024
pulisher
Aug 17, 2024

Regulus Therapeutics Reports Second Quarter 2024 Financial Resul - GuruFocus.com

Aug 17, 2024
pulisher
Aug 16, 2024

Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference - Longview News-Journal

Aug 16, 2024
pulisher
Aug 16, 2024

Oppenheimer Reiterates “Outperform” Rating for Regulus Therapeutics (NASDAQ:RGLS) - Defense World

Aug 16, 2024
pulisher
Aug 15, 2024

Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World

Aug 15, 2024
pulisher
Aug 14, 2024

Oppenheimer Reiterates Outperform Rating for Regulus Therapeutics (NASDAQ:RGLS) - MarketBeat

Aug 14, 2024
pulisher
Aug 14, 2024

Analyzing Regulus Therapeutics Inc (RGLS) After Recent Trading Activity - Knox Daily

Aug 14, 2024

Finanzdaten der Regulus Therapeutics Inc-Aktie (RGLS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):